Because we observed residual phosphorylation of the downstream PI3K target AKT in ibrutinib-treated CLL cells upon BCR stimulation, we subsequently studied the effects of combined BTK and PI3K inhibition on BCR-induced VLA-4 activation and could confirm an involvement of PI3K in this pathway [46]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.